“Nobody’s talking about this story,” Max Tokarsky said. Not exactly true, as the founder and CEO of InvestAcure is telling anyone who will listen. A former non-profit executive-turned-evangelist for the Impact Investment and Public Benefit Corporation model, Tokarsky is slated to present the keynote address at the Alzheimer's-2018 International Conference in Rome, Italy May 8. The Rome conference brings together researchers from around the world focused on groundbreaking research to slow, reverse or prevent dementia and Alzheimer’s disease. A life-long social entrepreneur and former non-profit executive, Tokarsky will present "The Enigma of Eroom’s Law and The Wall Street Math Stifling Alzheimer’s Drug Discovery" in Rome. He wants to talk about funding a cure for Alzheimer’s disease. But he’s not talking about just asking major corporations or the government or even Big Pharma for help. Tokarsky wants everyone to pitch in. And he’s figured out a way we can.
Buying a stock is one thing, but when do you sell? That question will have been nagging many nervous investors in recent months, after watching global stock markets tumble. One potential solution is to use stop-loss orders that ensure you exit your position when the price falls below a designated point. Do stop-loss orders work? Can they help investors sleep better at night by cutting back on risk? Or are stops a trader’s tool, best left to those who nip in and out of markets rather than investors with multiyear horizons?
Economist Andrew Lo talks to the FT's John Authers about his adaptive markets hypothesis, the idea that markets develop and adapt over time and should be modelled using concepts from biology instead of physics. It's the subject of his recent book, Adaptive Markets: Financial Evolution at the Speed of Thought.
Andrew W. Lo, director of the MIT Laboratory for Financial Engineering and the Charles E. and Susan T. Harris Professor at MIT, describes his research on artificial intelligence and financial markets at the launch event for the MIT Intelligence Quest, an Institute-wide initiative on human and machine intelligence research, its applications, and its bearing on society.
Derek Lowe's commentary on drug discovery and the pharma industry. An editorially independent blog from the publishers of Science Translational Medicine. All content is Derek’s own, and he does not in any way speak for his employer.
How do you drive investors to spend money on cutting-edge cancer treatments? One idea, according to economist Andrew Lo, is to sell securities in a megafund of research projects. Economics correspondent Paul Solman explores how financial engineering could be the starting point for curing cancer.
Andrew W. Lo was named winner of the $10,000 Harry M. Markowitz Award for his paper, "Moore's Law Vs. Murphy's Law in the Financial System: Who's Winning?" The award was announced Thursday by the Journal of Investment Management and New Frontier Advisors in a joint statement. The paper provided examples of technology capable of adapting to the "foibles in human behavior" so users can employ all the recent breakthroughs in computing hardware and software, data analytics and telecommunications that have changed the financial industry "safely, effectively and effortlessly," according to an abstract on the paper.